enGene Holdings Inc. (NASDAQ:ENGN) Receives $19.50 Average Price Target from Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $19.50.

Several equities research analysts have recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of enGene in a report on Saturday, September 27th. Morgan Stanley decreased their price objective on enGene from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, September 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of enGene in a report on Monday, September 8th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MAI Capital Management boosted its holdings in enGene by 11.0% in the first quarter. MAI Capital Management now owns 78,067 shares of the company’s stock valued at $350,000 after acquiring an additional 7,756 shares during the last quarter. Cresset Asset Management LLC acquired a new position in enGene in the second quarter valued at $36,000. Paloma Partners Management Co acquired a new position in enGene in the second quarter valued at $38,000. Jane Street Group LLC acquired a new position in enGene in the fourth quarter valued at $93,000. Finally, ADAR1 Capital Management LLC acquired a new position in enGene in the first quarter valued at $107,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Price Performance

ENGN stock opened at $7.60 on Thursday. enGene has a 52-week low of $2.65 and a 52-week high of $11.00. The stock’s fifty day simple moving average is $5.15 and its 200-day simple moving average is $4.28. The company has a quick ratio of 10.34, a current ratio of 10.34 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $389.06 million, a price-to-earnings ratio of -4.00 and a beta of -0.27.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Thursday, September 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Equities research analysts expect that enGene will post -1.56 EPS for the current year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.